SHAPE RNA Bioinformatics for Therapeutics and Translational Research

用于治疗和转化研究的 SHAPE RNA 生物信息学

• 批准号: 9046992
• 负责人: Kevin M Weeks
• 金额: $ 22.46万
• 依托单位: RIBOMETRIX, LLC
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-02 至 2018-09-01
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9046992
• 关键词: Adoption; Affect; Affinity; Antibiotics; Antisense Oligonucleotides; Area; Binding; Bioinformatics; Biological; Biological Markers; Biological Process; Biology; Cell physiology; Cellular Stress; Chemicals; Chemistry; Cloud Computing; Complex; Computational Biology; Computer Analysis; Computer software; Consult; Data; Diagnosis; Disease; Formulation; Genome; Gold; Government; HIV; Higher Order Chromatin Structure; Human Genome; Influenza; Laboratories; Ligands; Massive Parallel Sequencing; Medical; Messenger RNA; Methods; Modeling; Molecular Biology; Nucleic Acids; Nucleotides; Pharmaceutical Preparations; Pharmaceutical Services; Pharmacologic Substance; Phase; Process; Proteins; RNA; RNA Viruses; RNA analysis; Reading; Reporting; Research; Research Personnel; Resolution; Ribosomes; Role; Science; Services; Signal Transduction; Single Nucleotide Polymorphism; Site; Small Business Technology Transfer Research; Structure; System; Technology; Testing; Therapeutic; Transcript; Translating; Translational Research; Untranslated RNA; Validation; Viral Pathogenesis; Virus Replication; Vision; Work; base; design; digital; drug candidate; drug discovery; graduate student; high throughput technology; human disease; interest; laboratory development; novel; prototype; public health relevance; research study; small molecule; therapeutic development; therapeutic target; user-friendly

 DESCRIPTION (provided by applicant): Only 2% of the human genome is translated into proteins, whereas roughly 70% is transcribed into RNA. Complex higher-order structures in these RNAs fundamentally affect critical biological processes. As examples, RNA structures in the ribosome are the targets of many antibiotics, structures in the genomes of RNA viruses like HIV and influenza are essential for viral replication and pathogenesis, and roughly half of the single nucleotide polymorphisms that are most strongly associated with human diseases occur in non-coding regions and likely reflect abnormal RNA structures. These structures should be exploited in small-molecule drug discovery efforts. The Weeks laboratory has developed a chemical probing strategy, called SHAPE-MaP that accurately reports on RNA structure in physiologically relevant contexts. Although independent groups describe SHAPE as the "gold standard" of RNA structure analysis, in its current form, SHAPE-MaP represents a cutting-edge but research- grade technology. This technology is based on robust chemistry and "digital" massively parallel sequencing data and, in principle, could be fully automated. The long-term vision of Ribometrix is thus to make SHAPE-MaP a platform technology with applications in drug discovery, translational research, and basic biological discovery. In this work, we will conduct proof-of-concept studies to solve critical bioinformatic and computational impediments to adoption by non-expert laboratories via two Aims: (1) Create efficient commercial-grade software for automated deconvolution of massively parallel sequencing data into quantitative, validated SHAPE-MaP reactivity profiles and (2) Automate analysis pipelines to allow rapid modeling of RNA structures, discovery of candidate functional motifs, and quantification of ligand and drug candidate binding. Progress to Phase 2 will be justified by feasibility data showing that novice graduate student or technician-level users are able to analyze and diagnose RNA structure probing experiments and identify RNA features with likely functional importance using automated, error-tolerant software. In Phase 2, Ribometrix will fully refine and integrate automated computational analysis to be hosted on a shared cloud computing platform and will develop efficient consulting services for pharmaceutical and academic customers and collaborators. Widespread access to SHAPE technology will transform design of novel RNA-based therapeutics, discovery of RNA targets, and analysis and validation of small molecule-RNA interactions.